A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

The kinase inhibitor is now approved for adults and children aged ≥ 2 years with neurofibromatosis type 1 who have ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

The suzetrigine, which only acts on pain neurons, is the first innovation in analgesia in the last 20 years. "It stands out for its potency, but above all, in comparison with opioids, for its safety," ...

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for adults experiencing moderate to severe acute pain. Journavx received FDA ...

Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...

Nat Clin Pract Nephrol. 2006;2(3):136-148. Hypophosphatemia associated with primary hyperparathyroidism is usually of moderate severity; increased urinary phosphate excretion is balanced by ...

Among trial participants, the most common side effects of the drug were itching, muscle spasms, increased levels of creatine phosphokinase in the blood and rash. The medication should not be taken ...

A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives Daiichi Sankyo’s Turalio some company in a rare tumor type.

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

Serious adverse reactions occurred in 17% of adult patients who received GOMEKLI. The most common Grade 3 or 4 laboratory abnormality (>2%) was increased creatine phosphokinase. The most common ...